Spero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest Update

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw a large drop in short interest in the month of February. As of February 27th, there was short interest totaling 574,027 shares, a drop of 19.8% from the February 12th total of 715,694 shares. Currently, 1.1% of the company’s shares are short sold. Based on an average daily trading volume, of 270,567 shares, the days-to-cover ratio is currently 2.1 days. Based on an average daily trading volume, of 270,567 shares, the days-to-cover ratio is currently 2.1 days. Currently, 1.1% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on SPRO shares. Wall Street Zen raised shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, January 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Spero Therapeutics in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce”.

Insider Buying and Selling at Spero Therapeutics

In related news, insider Esther Rajavelu sold 87,917 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $2.36, for a total transaction of $207,484.12. Following the transaction, the insider owned 1,012,091 shares in the company, valued at $2,388,534.76. The trade was a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 5.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Spero Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Invesco Ltd. bought a new position in Spero Therapeutics during the 2nd quarter valued at $43,000. State Street Corp raised its holdings in shares of Spero Therapeutics by 10.1% in the fourth quarter. State Street Corp now owns 210,151 shares of the company’s stock valued at $490,000 after purchasing an additional 19,200 shares during the last quarter. Millennium Management LLC bought a new position in shares of Spero Therapeutics during the fourth quarter valued at about $56,000. Dimensional Fund Advisors LP bought a new position in shares of Spero Therapeutics during the third quarter valued at about $55,000. Finally, Quadrature Capital Ltd purchased a new position in Spero Therapeutics during the second quarter worth about $90,000. Institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Trading Up 0.4%

Shares of SPRO traded up $0.01 on Monday, reaching $2.59. The company’s stock had a trading volume of 97,677 shares, compared to its average volume of 304,527. Spero Therapeutics has a twelve month low of $0.51 and a twelve month high of $3.22. The stock has a market capitalization of $145.92 million, a PE ratio of -3.28 and a beta of 1.45. The firm has a fifty day moving average of $2.37 and a 200-day moving average of $2.28.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.